Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[COX-2 inhibitors--one step forward and two steps back].

Sigurd Evensen1, Olav Spigset, Lars Slørdal

  • 1Institutt for laboratoriemedisin, barne- og kvinnesykdommer, Norges teknisk-naturvitenskapelige universitet, 7489 Trondheim.

Tidsskrift for Den Norske Laegeforening : Tidsskrift for Praktisk Medicin, Ny Raekke
|April 9, 2005
PubMed
Summary

Selective cyclooxygenase-2 (COX-2) inhibitors offer no efficacy benefits over traditional NSAIDs and may increase adverse cardiovascular events. Caution is advised due to potential class-wide risks.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke·2026
Same author

Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke·2026
Same author

Subjective Memory Impairment in the General Adult Population: Associations With Early-Life Cognition, Concurrent Objective Memory, Dementia Risk Factors.

European journal of neurology·2026
Same author

Association Between Levels of the Acute Phase Proteins Alpha-1-Acid Glycoprotein and C-Reactive Protein and Serum Concentrations of Clozapine: A Study of 1106 Therapeutic Drug Monitoring Samples.

Basic & clinical pharmacology & toxicology·2026
Same author

Three-year adherence to secondary prevention and vascular risk control after ischemic stroke.

European stroke journal·2026
Same author

Written drug promotion from pharmaceutical companies to general practitioners: adherence to regulations over two decades.

European journal of clinical pharmacology·2025

Area of Science:

  • Pharmacology
  • Drug Safety
  • Cardiovascular Medicine

Context:

  • Selective cyclooxygenase-2 (COX-2) inhibitors are widely prescribed.
  • Concerns exist regarding their safety profile compared to conventional nonsteroidal anti-inflammatory drugs (NSAIDs).

Purpose:

  • To review the adverse effects of selective COX-2 inhibitors, including rofecoxib, celecoxib, etoricoxib, and valdecoxib.
  • To compare their safety and efficacy against traditional NSAIDs.

Summary:

  • Selective COX-2 inhibitors exhibit varying degrees of COX-2 selectivity.
  • Rofecoxib demonstrated a higher incidence of thromboembolic adverse effects.
  • Celecoxib's selectivity is comparable to diclofenac.

Impact:

Related Experiment Videos

  • Cardiovascular risks associated with rofecoxib may be a class effect for selective COX-2 inhibitors.
  • Comprehensive safety data is pending, necessitating cautious use of these agents.
  • The findings highlight the need for careful consideration of risks versus benefits.